Tango Therapeutics Statistics
Share Statistics
Tango Therapeutics has 107.42M shares outstanding. The number of shares has increased by 0.66% in one year.
| Shares Outstanding | 107.42M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.26% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 49.85M |
| Failed to Deliver (FTD) Shares | 145.40K |
| FTD / Avg. Volume | 7.32% |
Short Selling Information
The latest short interest is 8.06M, so 7.51% of the outstanding shares have been sold short.
| Short Interest | 8.06M |
| Short % of Shares Out | 7.51% |
| Short % of Float | 16.28% |
| Short Ratio (days to cover) | 4.51 |
Valuation Ratios
The PE ratio is -9.2 and the forward PE ratio is -2.56.
| PE Ratio | -9.2 |
| Forward PE | -2.56 |
| PS Ratio | 25.63 |
| Forward PS | 9.9 |
| PB Ratio | 3.7 |
| P/FCF Ratio | -7.83 |
| PEG Ratio | n/a |
Enterprise Valuation
Tango Therapeutics Inc. has an Enterprise Value (EV) of 908.80M.
| EV / Earnings | -8.93 |
| EV / Sales | 24.88 |
| EV / EBITDA | -8.13 |
| EV / EBIT | -7.96 |
| EV / FCF | -7.6 |
Financial Position
The company has a current ratio of 7.54, with a Debt / Equity ratio of 0.15.
| Current Ratio | 7.54 |
| Quick Ratio | 7.54 |
| Debt / Equity | 0.15 |
| Total Debt / Capitalization | 13.33 |
| Cash Flow / Debt | -3.03 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.4% and return on capital (ROIC) is -39.15%.
| Return on Equity (ROE) | -0.4% |
| Return on Assets (ROA) | -0.25% |
| Return on Capital (ROIC) | -39.15% |
| Revenue Per Employee | 260.91K |
| Profits Per Employee | -726.74K |
| Employee Count | 140 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 134.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -75.19% in the last 52 weeks. The beta is 0.88, so Tango Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.88 |
| 52-Week Price Change | -75.19% |
| 50-Day Moving Average | 3.48 |
| 200-Day Moving Average | 7.14 |
| Relative Strength Index (RSI) | 34.96 |
| Average Volume (20 Days) | 1.99M |
Income Statement
In the last 12 months, Tango Therapeutics had revenue of 36.53M and earned -101.74M in profits. Earnings per share was -1.08.
| Revenue | 36.53M |
| Gross Profit | -78.67M |
| Operating Income | -114.17M |
| Net Income | -101.74M |
| EBITDA | -111.76M |
| EBIT | -114.17M |
| Earnings Per Share (EPS) | -1.08 |
Balance Sheet
The company has 66.39M in cash and 38.92M in debt, giving a net cash position of 27.46M.
| Cash & Cash Equivalents | 66.39M |
| Total Debt | 38.92M |
| Net Cash | 27.46M |
| Retained Earnings | -371.26M |
| Total Assets | 352.42M |
| Working Capital | 263.23M |
Cash Flow
In the last 12 months, operating cash flow was -117.98M and capital expenditures -1.53M, giving a free cash flow of -119.51M.
| Operating Cash Flow | -117.98M |
| Capital Expenditures | -1.53M |
| Free Cash Flow | -119.51M |
| FCF Per Share | -1.26 |
Margins
Gross margin is -215.38%, with operating and profit margins of -312.57% and -278.54%.
| Gross Margin | -215.38% |
| Operating Margin | -312.57% |
| Pretax Margin | -278.18% |
| Profit Margin | -278.54% |
| EBITDA Margin | -305.96% |
| EBIT Margin | -312.57% |
| FCF Margin | -327.18% |
Dividends & Yields
TNGX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -41.22% |
| FCF Yield | -42.38% |
Analyst Forecast
The average price target for TNGX is $13, which is 396.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $13 |
| Price Target Difference | 396.2% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | -0.48 |
| Piotroski F-Score | 3 |